Table 1 Determination of antibacterial potency [MIC90 (µg/ml)] of BWC0977 and other known antibiotics performed at the International Health Management Associates (IHMA) against a global collection of Gram-negative drug-resistant clinical isolates

From: BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infections

 

A. baumannii

P. aeruginosa

E. coli

K. pneumoniae

E. cloacae

Proteus spp.

Citrobacter spp.

S. maltophilia

M. morganii

S. marcescens

N. gonorrhoeae

N

298

300

300

300

152

152

151

150

42

45

90

BWC0977

1

1

0.5

2

2

0.5

1

0.25

1

1

≤ 0.016

Ciprofloxacin

> 32

16

ND

> 32

ND

ND

ND

16

ND

ND

> 1

Levofloxacin

> 32

32

16

> 32

64

8

2

8

16

1

ND

aCefiderocol

4

2

2

2

4

0.5

2

2

1

1

ND

Cefepime

> 32

> 32

> 32

> 32

64

16

> 32

> 32

> 32

> 32

ND

Cefpodoxime

ND

ND

> 32

> 32

64

> 32

> 32

ND

> 32

> 32

ND

Ceftriaxone

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

0.06

Ceftazidime

> 32

>Z 32

64

> 64

128

2

> 64

> 32

16

8

ND

Ceftazidime-Avibactam

ND

> 16

0.25

1

2

0.06

0.5

ND

0.125

1

ND

Aztreonam

ND

> 16

> 64

> 64

128

0.5

64

ND

16

32

ND

Aztreonam/Avibactam

ND

> 16

0.125

0.25

0.5

≤ 0.016

0.25

ND

0.06

0.25

ND

Piperacillin/Tazobactam

> 128

128

ND

ND

0.06

ND

ND

> 128

ND

ND

ND

Meropenem

> 64

32

≤ 0.06

32

8

0.125

≤ 0.06

> 64

0.125

0.125

ND

Meropenem-vaborbactam

> 32

32

≤ 0.03

16

0.25

0.125

≤ 0.03

> 32

0.06

0.125

ND

Colistin

0.5

1

0.25

0.5

2

> 32

0.5

> 32

64

> 32

ND

Amikacin

 >64

64

8

32

4

4

4

> 64

8

8

ND

Gentamicin

> 32

> 32

> 32

> 32

1

16

8

> 32

64

16

ND

Doxycycline

64

32

32

32

16

> 32

16

4

64

16

ND

Eravacycline

ND

ND

0.25

1

ND

2

0.5

ND

1

2

ND

Tobramycin

> 32

> 32

16

> 32

32

8

8

> 32

16

32

ND

Plazomicin

ND

ND

1

0.5

0.5

4

0.5

ND

8

2

ND

  1. This study was part of a CARB-X screening programme to evaluate the activity of BWC0977 against a global panel of MDR bacterial pathogens (total of 2945 isolates) collected in 2019. In the case of N. gonorrhoea, the collection comprised of isolates identified from 1997 to 2021. BWC0977 showed excellent potency and broad-spectrum activity against these isolates (Gram-negative bacteria: Table 1, Gram-positive bacteria - Supplement section - Table 2). aCefiderocol MICs against same isolates were generated in a different study.